丁苯酞氯化钠注射液联合依达拉奉治疗急性脑梗死的效果及安全性

Efficacy and safety of butyphthalide sodium chloride injection combined with edaravone in the treatment of acute cerebral infarction

目的探讨丁苯酞氯化钠注射液联合依达拉奉治疗急性脑梗死效果及安全性。方法选自本院2016年3月至2017年3月急性脑梗死患者78例，按照随机分配原则，将其分为对照组与观察组，每组39例。对照组患者采用依达拉奉进行治疗，观察组则采用丁苯酞氯化钠注射液联合依达拉奉进行治疗。观察两组患者治疗前后神经功能缺损量表（NIHSS）评分、血清B型脑钠肽（BNP）水平、总有效率情况及Barthel指数（BI）进行评定情况。结果观察组采用丁苯酞氯化钠注射液联合依达拉奉治疗后，NIHSS评分及血清BNP水平明显低于对照组，差异有统计学意义（P〈0．05）；BI评分高于对照组，且总有效率高于对照组（97．44％比71．79％），差异有统计学意义（P〈0．05）。结论对于急性脑梗死患者临床上采用丁苯酞氯化钠注射液联合依达拉进行治疗，治疗效果更佳，可有效改善患者神经功能缺损，可提高生活质量，增加其安全性。

Objective To explore the efficacy and safety of butyphthalide sodium chloride injection combined with edaravone in the treatment of acute cerebral infarction. Methods From March 2016 to March 2017, 78 patients with acute cerebral infarction in our hospital were divided into control group and observation group according to the principle of random allocation, 39 cases in each group. The patients in the control group were treated with edaravone, and the patients in the observation group were treated with butyphthalide sodium chloride injection combined with edaravone. The neurological deficit scale （NIHSS） score, serum B type brain natriuretic peptide （BNP） level, total effective rate, and Barthel index （131） were observed before and after treatment in the two groups. Results After the treatment, the NIHSS score and serum BNP level of the observation group were significantly lower than those of the control group （P〈0.05）; the BI was higher than that of the control group, and the total effective rate was higher than that of the control group （97.44% vs.71.79%） （P〈0.05）. Conclusion For clinical patients with acute cerebral infarction, butyphthalide sodium chloride injection combined with edaravone can obtain better treatment effect, effectively improve the neurological deficit, improve the quality of life, increase the safety.